Download PDF
Nervenheilkunde 2011; 30(04): 229-237
DOI: 10.1055/s-0038-1627801
Schizophrenie
Schattauer GmbH

Pharmakotherapy in schizophrenia

Article in several languages: deutsch | English
H.-P. Volz
1   Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin Schloss Werneck, Werneck
,
O. Dietmaier
2   Zentrum für Psychiatrie, Psychotherapie und Kinder-und Jugendpsychiatrie, Klinikum am Weissenhof
› Author Affiliations
Further Information

Publication History

Eingegangen am: 30 June 2010

angenommen am: 31 August 2010

Publication Date:
23 January 2018 (online)

    Permissions and Reprints

Summary

The selection of the best antipsychotic for a schizophrenic patient is a demanding task. In this paper the most important selection criteria are discussed regarding the target syndrome (acute/longterm treatment, positive/ negative symptomatology, depressive symptomatology, cognitive deficits) as well as regarding tolerability and safety issues.

Keywords

Antipsychotics - schizophrenia - selection criteria
 

  • Literatur

  • 1 Allison DB. et al. Antipsychotic-induced weightgain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
    Google Scholar
  • 2 Amaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
    CrossrefGoogle Scholar
  • 3 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association of the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-72.
    CrossrefGoogle Scholar
  • 4 APA, American Psychiatric Association. Practice Guideline for the treatment of patients with schizophrenia. second edition. Am J Psychiatry. 2004. 161(2).
    Google Scholar
  • 5 Baas H. Parkinson-Syndrom. In: Förstl H. (Hrsg). Therapie neuropsychiatrischer Erkrankungen im Alter. München: Urban & Fischer. 2001
    Google Scholar
  • 6 Carillo JA. et al. Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119-27.
    CrossrefGoogle Scholar
  • 7 Csernansky JG, Mahmoud R, Brenner R. Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
    CrossrefGoogle Scholar
  • 8 Davis JM. Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry 1975; 132: 1237-45.
    CrossrefGoogle Scholar
  • 9 Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985; 46: 18-21.
    Google Scholar
  • 10 Degner D. et al. Qtc-Zeit-Verlängerung unter Amitriptylin in Kombination mit Ziprasidon. Psychopharmakotherapie 2010; 17: 51-4.
    Google Scholar
  • 11 DGPPN (Hrsg).. S3-Praxisleitlinien in Psychiatrie und Psychotherapie, Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag; 2006
    Google Scholar
  • 12 Falkai P. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005; 06: 132-91.
    CrossrefGoogle Scholar
  • 13 Fuchs WS. et al. Agranulozytose und Leukopenie unter Psychopharmaka mit Schwerpunkt Clozapin. Psychopharmakotherapie 2008; 15: 126-30.
    Google Scholar
  • 14 Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-82.
    CrossrefGoogle Scholar
  • 15 Green MF. et al. The neurocognitive effects of lowdose haloperidol: A two-year comparison with risperidone. Biol Psychiatry 2002; 51: 972-8.
    CrossrefGoogle Scholar
  • 16 Grimm SW. et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61: 58-69.
    CrossrefGoogle Scholar
  • 17 Harvey PD, Green MF, Keefe RSE, Velligan DI. Cognitive functioning in schizophrenia: A consensus statement on its role in the definition and evaluation of affective treatments for the illness. J Clin Psychiatry 2004; 65: 361-72.
    CrossrefGoogle Scholar
  • 18 Hatta K. et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Res 2009; 113: 49-55.
    CrossrefGoogle Scholar
  • 19 Hiemke C. et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-81.
    Google Scholar
  • 20 Kraus JE. et al. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J Clin Psychiatry 2005; 66: 1564-8.
    CrossrefGoogle Scholar
  • 21 Lambreva E. et al. Neurotoxische Enzephalopathie unter Neuroleptika und Lithium. Nervenarzt 2005; 76: 756-9.
    CrossrefGoogle Scholar
  • 22 Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medication. Am J Psychiatry 2004; 161: 1709-11.
    CrossrefGoogle Scholar
  • 23 Leucht S. et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomised, controlled trials. Am J Psychiatry 2003; 160: 1209-22.
    CrossrefGoogle Scholar
  • 24 Leucht S. et al. Second generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
    CrossrefGoogle Scholar
  • 25 Leucht S, Kissling W, Davis JM. Second generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychological Medicine 2009; 39: 1591-602.
    CrossrefGoogle Scholar
  • 26 McCue R. et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Brit J Psychiatry 2006; 189: 433-40.
    CrossrefGoogle Scholar
  • 27 Messer T, Schmauß M. Polypharmazie in der Behandlung psychischer Erkrankungen. Wien: Springer; 2009
    Google Scholar
  • 28 Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013-22.
    CrossrefGoogle Scholar
  • 29 Möller HJ. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms. Eur Arch Psychiatry Clin Neurosci 2001; 251: 217-24.
    CrossrefGoogle Scholar
  • 30 Murphy BP. et al. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Res 2006; 88: 5-25.
    CrossrefGoogle Scholar
  • 31 NICE (National Institute for Clinical Excellence). 2003. Core Interventions in the Treatment of Schizophrenia. NICE, London. (www.nice.org.uk).
    Google Scholar
  • 32 Raja M, Azzoni A. Comparison of three antipsychotics in the emergency psychiatric setting. Hum Psychopharmacol 2003; 18: 447-52.
    CrossrefGoogle Scholar
  • 33 Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews. 2006 3, Art. No.: CD005581.DOI:10.1002 /14651858.CD005581.pub2.
    Google Scholar
  • 34 Rupprecht alR. Zur Problematik der Kombination von Clozapin mit Benzodiazepinen. Nervenarzt 2004; 76: 857-60.
    Google Scholar
  • 35 Schäfer I, Lambert M, Naber D. Atypische Antipsychotika bei therapieresistenter Schizophrenie. Nervenarzt 2004; 75: 79-91.
    CrossrefGoogle Scholar
  • 36 Schneeweiss MD, Avorn J. Antipsychotic agents and sudden cardiac death – how should we manage the risk?. N Engl J Med 2009; 306: 294-6.
    Google Scholar
  • 37 Seppala NH. et al. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999; 85: 244-6.
    CrossrefGoogle Scholar
  • 38 Spina E. et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002; 22: 419-23.
    CrossrefGoogle Scholar
  • 39 Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000; 14: 409-18.
    CrossrefGoogle Scholar
  • 40 Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4.
    CrossrefGoogle Scholar
  • 41 Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002; 56: 1-10.
    CrossrefGoogle Scholar
  • 42 Volz HP, Reischies F, Riedel M. Kognitive Störungen bei schizophrenen Patienten. Nervenarzt 2010; 81: 39-54.
    Google Scholar
  • 43 Volz HP, Dietmaier O. Welches Antipsychotikum für welchen Patienten. Der Neurologe und Psychiater 2010; 09 (09) 55-61.
    Google Scholar
  • 44 Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine´s effectiveness in schizophrenia: A systematic review and meta-analysis of randomised trials. Am J Psychiatry 1999; 156: 990-9.
    Google Scholar
  • 45 Woodward ND. et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 08: 457-72.
    CrossrefGoogle Scholar
  • 46 Zullino DF. et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17: 141-3.
    CrossrefPubMedGoogle Scholar